ArticleHistopathology2015
MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.
Article in Histopathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 97 citations in OpenAlex.
- Landscape of genetic alterations affecting cancer genes in primary and advanced malignant phyllodes tumours.Histopathology · 2026Article
- Emerging biomarkers in breast fibroadenoma: implications for differential diagnosis, malignant transformation, and precision medicine.Molecular biology reports · 2026Review
- Molecular pathology of phyllodes tumours of the breast-much more than MED12.Histopathology · 2026Review
- Giant Malignant Phyllodes Tumor with Secondary Thyroid Involvement.Diseases (Basel, Switzerland) · 2026Article
- Contemporary management of phyllodes tumours of the breast: recommendations from the UK Association of Breast Surgery.The British journal of surgery · 2025Article
- MED12 dysregulation: insights into cancer and therapeutic resistance.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Recent Advances in Malignant Phyllodes Tumors of the Breast.Journal of breast cancer · 2025Review
- Borderline Phyllodes Breast Tumors: A Comprehensive Review of Recurrence, Histopathological Characteristics, and Treatment Modalities.Current oncology (Toronto, Ont.) · 2025Review
- Benign tumors broaden the field of application for immunotherapy.Frontiers in immunology · 2025Review
- Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- A Comprehensive Review of Breast Fibroadenoma: Correlating Clinical and Pathological Findings.Cureus · 2023Review
- Periductal Stromal Tumor of the Breast with aInternational journal of surgical pathology · 2023Article
- Changes in the mammary gland during aging and its links with breast diseases.Acta biochimica et biophysica Sinica · 2023Review
- Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction.Histopathology · 2023Review
- Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment.Endocrine reviews · 2022Review
- Spindle cell lesions of the breast: a diagnostic approach.Virchows Archiv : an international journal of pathology · 2022Review
- Effects of miRNA-199a-5p on cell proliferation and apoptosis of uterine leiomyoma by targeting MED12.Open medicine (Warsaw, Poland) · 2022Article
- Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Integrated mutational landscape analysis of uterine leiomyosarcomas.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Fibroepithelial lesions revisited: implications for diagnosis and management.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
Abstract
aimsSomatic mutations in exon 2 of the mediator complex subunit 12 (MED12) gene have been identified in 60% of breast fibroadenomas (FAs). The aim of this study was to define whether phyllodes tumours (PTs) would harbour MED12 somatic mutations in a way akin to FAs. METHODS AND
resultsA collection of 73 fibroepithelial tumours (including 26 FAs, 25 benign PTs, nine borderline PTs and 13 malignant PTs) from 64 patients was retrieved from the authors' institution. Sections from formalin-fixed paraffin-embedded (FFPE) blocks were microdissected to ensure an enrichment in neoplastic stromal elements of >70%. DNA samples extracted from tumour and matched normal tissues were subjected to Sanger sequencing of exon 2 of the MED12 gene. MED12 exon 2 somatic mutations, including 28 somatic single nucleotide variants and 19 insertions and deletions, were found in 65%, 88%, 78% and 8% of FAs, benign PTs, borderline PTs and malignant PTs, respectively. Malignant PTs harboured MED12 exon 2 somatic mutations significantly less frequently than FAs, benign and borderline PTs.
conclusionsAlthough MED12 exon 2 somatic mutations probably constitute the driver genetic event of most FAs, benign and borderline PTs, our results suggest that the majority of malignant PTs may be driven by other genetic/epigenetic alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.